As a novel ultra-short-acting benzodiazepines drugs, Remimazolam has been accepted for induction and maintenance of clinical anesthesia. Compared to the traditional benzodiazepines drugs, Remimazolam combines the safety of midazolam with the effectiveness of propofol, and also has the advantages of acting quickly, short half-life, no injection pain, slight respiratory depression, independent of liver and kidney metabolism, long-term infusion without accumulation, and has a specific antagonist: flumazenil. This study aims to investigate whether Remimazolam reduces the incidence of emergence agitation in children after ophthalmic surgery, compared to sevoflurane (RCT).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The incidence of emergence agitation
Timeframe: Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes
The incidence of emergence agitation
Timeframe: Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes
The incidence of emergence agitation
Timeframe: Duration from the time patients arrived the post-anesthesia care unit to the time of leaving to the ward, average 30 minutes